Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples